©2025 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2024

Optogenetics for RP: 12-Month Data

Allen Ho, MD

Show Description +

Allen Ho, MD, highlights the 12-month data from the phase 2b/3 clinical trial of low- or high-dose MCO-010 (Nanoscope Therapeutics) mutation agnostic optogenetic therapy for retinitis pigmentosa.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

Retinitis pigmentosa

•

Clinical Trials

•

MCO-010

•

Nanoscope Therapeutics

•

mutation agnostic

•

optogenetic therapy

Up Next

New Data on Oral DR Therapy
New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?
Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT
Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President
SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Gene Therapy for Wet AMD: Pharmacodynamic Changes
Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Faricimab in the Real World: 2 Years of Data
Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Addressing the AMD Epidemic
Addressing the AMD Epidemic

Emily Chew, MD

Managing Concurrent Wet AMD and GA
Managing Concurrent Wet AMD and GA

Ted Leng, MD

A Look at Three-Year Data for Pegcetacoplan
A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

The Latest Data on Photobiomodulation
The Latest Data on Photobiomodulation

Todd Schneiderman, MD

A Subretinal Implant for GA: Improving Vision
A Subretinal Implant for GA: Improving Vision

Mahi Muqit, MD

link-arrow   Back to All Videos

Optogenetics for RP: 12-Month Data

Allen Ho, MD

Allen Ho, MD, highlights the 12-month data from the phase 2b/3 clinical trial of low- or high-dose MCO-010 (Nanoscope Therapeutics) mutation agnostic optogenetic therapy for retinitis pigmentosa.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

Retinitis pigmentosa

•

Clinical Trials

•

MCO-010

•

Nanoscope Therapeutics

•

mutation agnostic

•

optogenetic therapy

Please log in to leave a comment.

More From ARVO: 2024 Coverage

New Data on Oral DR Therapy
New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?
Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT
Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President
SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2024.

close-x